Adiuvo Investment SA (ADV) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 9 Million ()

P/E

3.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.76

Return on Equity

-4.41%

Price to Book

-0.25

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Mar 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-14.63%

6 Months

-31.52%

1 Year

93.85%

2 Years

-43.75%

3 Years

-13.22%

4 Years

-78.2%

5 Years

-87.4%

Adiuvo Investment SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-9.83%

EBIT Growth (5y)

13.18%

EBIT to Interest (avg)

-9.79

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

-0.06

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-0.27

EV to EBIT

-16.25

EV to EBITDA

-20.23

EV to Capital Employed

-4.55

EV to Sales

34.72

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 33.33% vs 200.00% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 125.00% vs -50.00% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "-2.40",
          "chgp": "120.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.90",
          "chgp": "11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.60",
          "val2": "-2.40",
          "chgp": "125.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "873.50%",
          "val2": "-8,026.20%",
          "chgp": "889.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -70.00% vs 400.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 77.27% vs 81.00% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "1.00",
          "chgp": "-70.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.20",
          "val2": "-5.10",
          "chgp": "37.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "2.80",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.10",
          "val2": "-1.20",
          "chgp": "-491.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-11.00",
          "chgp": "77.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,793.40%",
          "val2": "-5,194.90%",
          "chgp": "-459.85%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.40

0.30

33.33%

Operating Profit (PBDIT) excl Other Income

0.50

-2.40

120.83%

Interest

1.00

0.90

11.11%

Exceptional Items

0.00

Consolidate Net Profit

0.60

-2.40

125.00%

Operating Profit Margin (Excl OI)

873.50%

-8,026.20%

889.97%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 33.33% vs 200.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 125.00% vs -50.00% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.30

1.00

-70.00%

Operating Profit (PBDIT) excl Other Income

-3.20

-5.10

37.25%

Interest

0.70

2.80

-75.00%

Exceptional Items

-7.10

-1.20

-491.67%

Consolidate Net Profit

-2.50

-11.00

77.27%

Operating Profit Margin (Excl OI)

-9,793.40%

-5,194.90%

-459.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -70.00% vs 400.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 77.27% vs 81.00% in Dec 2023

All Annual Results

Company CV

About Adiuvo Investment SA

Adiuvo Investment SA

Pharmaceuticals & Biotechnology

Adiuvo Investments SA is a Poland-based company engaged in the financial industry. The Company focuses on the selection, development, financing and commercialization of biomedical projects on the international market. By providing intellectual property protection, technology validation in clinical trials and obtaining certificates allowing products to market, Adiuvo Investments SA is able to commercialize projects in diverse business model and internationally. The Company is looking for and invests in projects in the segments of the nutraceutical, medical devices and the digital health. Its business portfolio encompasses Airway Medix, Algae Labs, Carocelle, Cambridge Chocolate Technology, Endomedical, Esthechoc, Glia, Joint Polish Investment Fund, Marmar Investment, Nanoxide and Peptaderm.

Company Coordinates

Company Details

Ul. Gen. Jozefa Zajaczka 11/14 , WARSZAWA None : 01-510

Tel: 48 22 408448048 22 4909401

http://www.adiuvoinvestments.com

Registrar Details